Altimmune, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2021-03-01

Reporting Person: Hodges Philip (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock, par value $0.0001	S	6000	$16.08	Disposed	8731	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	17848	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.56, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The shares of Common Stock are owned directly by Paradigm Venture Partners, L.P. The reporting person has sole voting and dispositive control with respect to all securities held by Paradigm Venture Partners, L.P. and may be deemed to be the beneficial owner of the securities held by Paradigm Venture Partners, L.P. The reporting person disclaims beneficial ownership of the securities held by Paradigm Venture Partners, L.P. except to the extent of his pecuniary interest therein.